Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
Safety of SGLT2 inhibitors in active cancer patients: Rationale and study design of TOSCA trial
Anno:
2024
Background: SGLT2 inhibitors have dramatically improved the outcome of heart failure patients with both preserved (HFpEF), mildly reduced (HFmrEF) and reduced (HFrEF) ejection fraction. Cancer patients have been excluded (or not enrolled) from pivotal trials so data on safety in such population are lacking. We aimed to collect evidence…
Leggi di più
EFFECT OF SGLT2 INHIBITORS ON THE ARRHYTHMIC BURDEN IN HEART FAILURE
Anno:
2024
Background: Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) have shown significant cardiovascular benefits in patients with and without type 2 diabetes mellitus, however, their potential beneficial effect on arrhythmic burden has been poorly investigated. Objective: this observational study explores the potential arrhythmic burden reduction in a cohort of heart failure (HF)…
Leggi di più

A.N.M.C.O. – Via La Marmora 36, 50121 Firenze (Italy) – Partita I.V.A. 05469530488 – Codice Fiscale 01301130488 – Privacy
www.anmco.it | segreteria@anmco.it

Cookie Policy Privacy Policy

Seguici su

Facebook Twitter Youtube Linkedin Instagram Telegram